Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Kontinuerlig glukosövervakning och beteendeförändringsintervention för personer med typ 2-diabetes och diabetesnöd

25 augusti 2026 uppdaterad av: Northwell Health

Kontinuerlig glukosövervakning i kombination med fjärrtillförda beteendeförändringsteknikinterventioner för glykemisk hantering och diabetesnöd bland vuxna med typ 2-diabetes

The purpose of this study is to use a Personalized Trial (N-of-1) design to test the effect of an intervention that pairs continuous glucose monitoring (CGM) with text message-delivered behavior change interventions for physical activity and mood on outcomes of glycemic regulation and diabetes distress among adults with type 2 diabetes and diabetes distress. Participants (n=60) will be given CGM sensors and a FitBit watch to wear during the 10-week study. Participants will complete a two-week baseline/run-in period, during which the participants usual blood glucose and physical activity will be monitored. After successful completion of the run-in period, participants will enter an eight-week intervention period, during which the participant will be randomized to either of two arms, which will both receive two interventions in alternating order - 1) CGM paired with behavioral intervention for physical activity and 2) CGM paired with behavioral intervention for mood. Every two weeks, participants will complete self-report measures assessing mood and health-related behavior and a hemoglobin A1C test. At the end of the trial, participants will receive a summary of the data to help the participants learn more about the responses to the two interventions and to inform investigators about the feasibility of an N-of-1 study design for future research and clinical applications.

Studieöversikt

Detaljerad beskrivning

The purpose of this study is to use a Personalized Trial (N-of-1) design to test the effect of an intervention that pairs continuous glucose monitoring (CGM) with text message-delivered behavior change interventions for physical activity and mood on outcomes of glycemic regulation and diabetes distress among adults aged ≥45 years with type 2 diabetes and diabetes distress. This study will explore the feasibility of using a Personalized Trial (n-of-1) design for widespread use in future research and clinical practice in populations with type 2 diabetes.

Participants (n=60) will be recruited into a 10-week Personalized Trial consisting of a two-week baseline/run-in period and an eight-week intervention period. Two interventions will be delivered to each participant: 1) CGM paired with behavioral intervention for physical activity and 2) CGM paired with behavioral intervention for mood. Both interventions will include the use of CGM paired with a behavioral intervention delivered via mobile technology using behavior change techniques of self-monitoring and action planning. After completing the two-week baseline/run-in period, participants will be randomly assigned into one of two arms. In one arm, participants will receive CGM plus the physical activity behavior change technique intervention in weeks 1-2 and 7-8 and the mood intervention during weeks 3-6 of the intervention period. In the second arm, participants will receive the opposite interventions to the first arm.

Participants will be provided and asked to use Freestyle Libre CGM sensors that will monitor the participants blood glucose levels and a Fitbit watch that will track the participants physical activity. The participant will complete measures assessing diabetes distress, diabetes self-management behavior frequency, depressive symptom severity, and health-related problem-solving once every two weeks. The participant will be sent and asked to return a self-administered hemoglobin A1C test every two weeks. At the end of the participants participation, participants will receive a summary of the data to help the participant learn more about the responses to the two interventions and to inform investigators about the feasibility of an N-of-1 study design for future research and clinical applications.

Studietyp

Interventionell

Inskrivning (Faktisk)

3

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New York
      • New York, New York, Förenta staterna, 10030
        • Northwell Health - Institute of Health System Science

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

45 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults aged 45 years or older
  • Diagnosis of type 2 diabetes
  • Suboptimal hemoglobin A1C (≥8.0%)
  • Positive screen for diabetes distress (Diabetes Distress Scale≥3.0)
  • Access to and capable of using a smart cellular phone
  • Ambulatory and never informed by clinician that it was not advisable/safe to participate in a low-intensity walking

Exclusion Criteria:

  • Currently on dialysis
  • Inability to comply with study protocol during 2-week run-in
  • Currently using CGM
  • Does not speak English
  • Unavailable for follow-up
  • Pregnancy

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Hälsovårdsforskning
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: CGM paired with behavior change technique interventions, physical activity intervention first

Participants in this arm will receive a continuous glucose monitor and they will receive two behavior change technique interventions via daily text messages over the course of eight weeks, in a series of four, two-week blocks. In the first two-week block, they will receive the physical activity behavior change technique intervention. In the second and third two-week blocks, they will receive the mood behavior change technique intervention. In the fourth two-week block, they will receive the physical activity behavior change technique intervention.

Self-Monitoring of Behavior for Physical Activity: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring the number of steps taken on the prior day relative to their baseline average number of steps.

Action Planning for Physical Activity: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to walk an extra 1,000 steps relative to their baseline average step count.

Self-Monitoring of Behavior for Mood: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring their mood on the prior day.

Action Planning for Mood: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to improve their mood.

Experimentell: CGM paired with behavior change technique interventions, mood intervention first

Participants in this arm will receive a continuous glucose monitor and they will receive two behavior change technique interventions via daily text messages over the course of eight weeks, in a series of four, two-week blocks. In the first two-week block, they will receive the mood behavior change technique intervention. In the second and third two-week blocks, they will receive the physical activity behavior change technique intervention. In the fourth two-week block, they will receive the mood behavior change technique intervention.

Self-Monitoring of Behavior for Physical Activity: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring the number of steps taken on the prior day relative to their baseline average number of steps.

Action Planning for Physical Activity: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to walk an extra 1,000 steps relative to their baseline average step count.

Self-Monitoring of Behavior for Mood: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring their mood on the prior day.

Action Planning for Mood: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to improve their mood.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean Within-Subject Difference in Glucose Time in Range
Tidsram: Measured continuously during the 10-week study. Averages are computed for baseline/run-in (2 weeks) and intervention (8 weeks; grouped in 4 blocks of 2 weeks) periods. Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Time in range will be measured continuously using the Freestyle Libre CGM. Participants will place a CGM sensor every two weeks throughout the 10-week study. Time in range will be aggregated to compute the percent of time (0-100%) that a person spends with their blood glucose levels in the target range of 70-180 mg/dL for each assessment time period (the two-week baseline/run-in and the four two-week intervention blocks). Higher time in range values reflect better blood glucose management. Scores for the two-week intervention blocks will be aggregated. Paired samples t-tests will examine pre-post changes comparing the aggregated post-intervention value to baseline/run-in, with separate analyses for each intervention.

Measured continuously during the 10-week study. Averages are computed for baseline/run-in (2 weeks) and intervention (8 weeks; grouped in 4 blocks of 2 weeks) periods. Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.
Mean Within-Subject Difference in Diabetes Distress
Tidsram: Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Diabetes distress will be measured using the Diabetes Distress Scale (DSS), a valid and reliable 17-item measure that assesses emotional distress in the setting of diabetes. Item responses range from 1 "not a problem" to 6 "a very serious problem." At each assessment timepoint, a total score will be computed by averaging items. Total scores range from 1 to 6, with higher scores reflecting greater diabetes distress . Scores for the two-week intervention blocks will be aggregated. Paired samples t-tests will examine pre-post changes comparing the aggregated post-intervention value to baseline/run-in, with separate analyses for each intervention.

Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean Within-Subject Difference in Steps Per Day
Tidsram: Measured continuously during the 10-week study. Average are computed for baseline/run-in (2 weeks) and intervention (8 weeks; grouped in 4 blocks of 2 weeks) periods. Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Steps per day will be continuously measured using a Fitbit. Daily steps will be aggregated to generate average steps per day for each assessment time period (the two-week baseline/run-in and the four two-week intervention blocks).

Measured continuously during the 10-week study. Average are computed for baseline/run-in (2 weeks) and intervention (8 weeks; grouped in 4 blocks of 2 weeks) periods. Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.
Mean Within-Subject Difference in Diabetes Self-Management Behaviors
Tidsram: Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Diabetes self-management behavior will be assessed using the Summary of Diabetes Self-Care Activities Scale (SDSCA), a valid and reliable 12-item measure that assesses the frequency of engaging in activities for diabetes self-care. The Summary of Diabetes Self-Care Activities Scale is comprised of the following subscales: general diet, specific diet, exercise, blood glucose testing, foot care, and smoking. Item responses range from 0 days to 7 days. At each assessment timepoint, subscale scores will be computed by averaging items to identify the mean number of days engaging in each behavior. Subscale scores range from 0 to 7, with higher scores reflecting more frequent engagement in that behavior.

Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.
Mean Within-Subject Difference in Depressive Symptom Severity
Tidsram: Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Depressive symptom severity will be assessed using the Patient Health Questionnaire-8, a valid and reliable 8-item measure assessing the frequency of experiencing symptoms of depression over the past two weeks. Item responses range from 0 "not at all" to 3 "nearly every day." At each timepoint, a total score will be computed by summing all items. Total scores range from 0 to 24, with higher scores reflecting greater depressive symptom severity.

Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.
Mean Within-Subject Difference in Health-Related Problem-Solving
Tidsram: Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Health-related problem-solving will be assessed using two subscales Health Problem-Solving Scale (HPSS). The Health Problem-Solving Scale is a valid and reliable measure of problem-solving orientation and skills in the context of health. Item responses range from 0 "not at all true of me" to 4 "extremely true of me." At each timepoint, subscale scores will be computed for the Avoidant subscale (7 items; range: 0-28) and Impulsive/Careless subscale (8 items, range: 0-32), with higher scores reflecting more of that problem-solving style.

Assessed at the end of the baseline/run-in period (2 weeks duration) and every 2 weeks during the intervention period (8 weeks duration; grouped in 4 blocks of 2 weeks). Data are aggregated, averaging 2 blocks for physical activity and 2 blocks for mood.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 september 2024

Primärt slutförande (Faktisk)

28 februari 2025

Avslutad studie (Faktisk)

28 februari 2025

Studieregistreringsdatum

Först inskickad

29 juni 2023

Först inskickad som uppfyllde QC-kriterierna

7 juli 2023

Första postat (Faktisk)

12 juli 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All collected IPD will be de-identified and pooled before sharing on the Open Science Framework, along with a data dictionary.

Tidsram för IPD-delning

The study protocol, including the statistical analysis plan, will be made available in addition to the informed consent following completion of recruitment but prior to the publication of any data from the current study. De-identified, pooled individual participant data will be made available within a year of final participant data collection. The investigators anticipate this data will be available on the Open Science Framework platform indefinitely.

Kriterier för IPD Sharing Access

All data and supporting information will be stores on the Open Science Framework, a free web application with no access restrictions.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera